Annual Report 2014: Progress continues for Orifarm

Denmark's biggest supplier of pharmaceuticals, Orifarm Group, continues its positive development. The annual results for 2014 shows an increase in revenue and an improved operating result, not least due to a significant improvement in the business area of generic medications.

Orifarm Group is the largest parallel importer of pharmaceuticals in Europe and the largest supplier of pharmaceutical products in Denmark. The company has in recent years shown improvement and the positive trends continue in the financial statements for 2014.

It shows an increase in revenue of 4% and an improvement in profit before tax by DKK 8 million. It is first and foremost the strategic initiatives and adjustments which were launched in 2012/2013, which now appears on the company's top and bottom line.

Overall, net sales increased from EUR 724 million in 2013 to EUR 750 million in 2014.
Operating profit increased by EUR 0.4 million to EUR 1.63 million. The total profits before tax is EUR 8.7 million, which is an increase of EUR 1.07 million compared to 2013.

For more information please contact:
CEO Orifarm Group A/S, Hans Bøgh-Sørensen, + 45 29 74 27 10
CEO Orifarm PI A/S, Erik Sandberg, +45 22 65 01 21
CEO Orifarm Generics A/S, Ulrik Ernst Rasmussen, +45 22 65 01 91


Download annual report